StockpollyBeta
Get App
Popularity #1,537
GSK · NYSE · Drug Manufacturers - General

GSK (ADR) (GSK)

Develops specialty medicines and vaccines through immune-system science and advanced technologies.

$50.22
vs last close−0.86 (−1.68%)
Loading prices…

Something off on this page? Send us feedback.

GSK plcGSK
Health Care

Develops specialty medicines, vaccines, and general medicines across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. Research combines immune-system science with advanced technologies, while the business depends on clinical development, regulatory approvals, reimbursement, intellectual-property protection, and manufacturing continuity.

Develops and sells specialty medicines, vaccines, and general medicines, with research centered on immune-system science and advanced technologies. Key therapeutic areas include respiratory, immunology and inflammation, oncology, HIV, and infectious diseases, supported by products such as Nucala, Dovato, Shingrix, Arexvy, and Trelegy.

Operates from London with a workforce spread across Europe, the United States, and international markets. Long-running capabilities in respiratory medicine, vaccines, and HIV now sit within a focused biopharma portfolio after the separation of consumer health as Haleon.

Depends on successful clinical development, regulatory approvals and labels, reimbursement, intellectual-property protection, and reliable manufacturing. HIV economics and development are partly organized through ViiV Healthcare, while product availability and approved uses vary by jurisdiction.

Company facts

CEOLuke Miels
ListedJul 22, 2022
ExchangeNYSE
HeadquartersLondon, UK
CountryUnited Kingdom
Employees66,841
CIK0001131399
ISINUS37733W2044

Market cap$102.34B
EPS (ttm)$3.17
P/E (ttm)16.14
ROE24.4%
P/B4.37
P/S2.31
Dividend yieldDiv yield3.56%
Beta0.28vs XLV 1.04

Price target$60.00+17.5%Average of 29 analysts
ConsensusHold16 of 29 analysts
Ratings

Target rangeAs of Sep 21, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Sep 15, 2026Berenberg BankTarget
Target: —
Target: $60
Sep 8, 2026RBC CapitalInitiate
Rating: —
Rating: Sector Perform
Jul 6, 2026HSBCUpgrade
Rating: Reduce
Rating: Hold
Jan 6, 2026BarclaysDowngrade
Rating: Equal Weight
Rating: Underweight
Oct 30, 2025CFRATarget
Target: —
Target: $53

Next report
Oct 28, 26
in 36 days
EPS estimate
$1.37
Revenue estimate
$11.97B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$0.59$1.13$1.23$1.48$0.68$1.24$1.36Pending
Estimate$0.44$1.08$1.12$1.26$0.64$1.16$1.27$1.37
Surprise+34.1%+4.6%+9.8%+17.5%+6.3%+6.9%+7.1%—

RevenueReportedEstimate

Feb '25Apr '25Jul '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$10.16B$10.04B$10.61B$11.32B$11.78B$10.30B$11.18BPending
Estimate$9.54B$9.72B$10.50B$11.04B$11.41B$10.23B$11.02B$11.97B
Surprise+6.5%+3.3%+1.1%+2.6%+3.2%+0.7%+1.4%—
Estimate$1.37
ReportedDue Oct 28, 2026
Estimate$11.97B
ReportedDue Oct 28, 2026
View details

Debt to equity103.40%
Current ratio81.50%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$10.70B$10.84B$10.04B$10.67B$11.42B$11.51B$10.19B$11.23B
Net income−$77.5M$552.9M$2.17B$1.93B$2.69B$849.4M$2.32B$581.0M
Net margin0.0%5.1%21.6%18.1%23.6%7.4%22.8%5.2%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$252.4M$929.6M$2.96B$2.70B$3.46B$2.01B$3.06B$642.4M
YoY growth−90.3%+21.5%+48.7%+22.9%+1,272.0%+116.4%+3.5%−76.2%

Balance sheet, Jun 30, 2026Cash & short-term investments $4.12B · Total debt $24.21B · Total assets $81.96B · Shareholders' equity $23.42B

Revenue
$11.23B
Operating income
$642.4M
Net income
$581.0M

Reported in GBP, converted at the latest exchange rate

View details

Dividend yield
3.56%
Next ex-date
Nov 14, 26
estimated · in 53 days
Annual dividend
$1.82
per share
Schedule
Quarterly
4 payments a year

HistoryDividendAnnual yield

Nov '24Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26
Dividend$0.3891$0.4007$0.4348$0.43$0.4331$0.4776$0.455$0.4515
Annual yield4.67%4.23%4.28%4.20%3.60%2.98%3.62%3.67%
Ex-dateNov 15Feb 21May 16Aug 15Nov 14Feb 20May 15Aug 14
Payment dateJan 9Apr 10Jul 10Oct 9Jan 8Apr 9Jul 9Oct 8
View details

Institutions16.09%347.23M ADS
1,078 holders · as of Jun 30, 2026
Other83.91%1.81B ADS
remainder

2.16B ADS (1 ADS = 2 ordinary shares) as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
FMR LLCInstitution
3.01%64.96M ADSas of Jun 30, 2026
Dodge & CoxInstitution
2.23%48.20M ADSas of Jun 30, 2026
Fisher Asset Management, LLCInstitution
1.66%35.72M ADSas of Jun 30, 2026
Primecap Management Co/CA/Institution
1.17%25.18M ADSas of Jun 30, 2026
Wellington Management Group LLPInstitution
0.53%11.40M ADSas of Jun 30, 2026

Insider tradesForm 4

Nothing filed in the last 12 months.

View details

  • AstraZeneca (ADR)

    Broad respiratory rival with targeted oncology and vaccine overlap

  • Pfizer

    Global biopharma rival across vaccines and oncology

  • Sanofi (ADR)

    Broad overlap in respiratory biologics, vaccines and multiple myeloma

  • Merck

    Major competitor across vaccines, oncology and HIV treatment

  • Gilead Sciences

    Competes across HIV treatment, HIV prevention and oncology

  • Bristol-Myers Squibb

    Global biopharma focused on oncology, hematology and immunology

  • Novartis (ADR)

    Competes in respiratory biologics and myelofibrosis therapies

Compare

CompanyPriceChange
GSK (ADR)$50.22−1.68%$102.34B16.19.22.3+5.3%
AstraZeneca (ADR)$166.77−0.79%$260.70B25.215.74.2+6.4%
Pfizer$27.53−0.76%$158.10B36.79.82.5+2.6%
Sanofi (ADR)$42.04−1.08%$102.05B75.6—1.8+11.2%
Merck$148.16−0.90%$369.24B119.617.25.6+5.1%
Gilead Sciences$148.81−1.16%$186.93B—16.46.1+10.2%
Bristol-Myers Squibb$62.06−0.89%$127.91B13.89.72.6+5.7%
Novartis (ADR)$140.14−0.60%$267.96B21.314.94.8+0.9%
Median30.915.34.2+5.7%